Imperial College London
Portrait Picture

DrJonathanKrell

Faculty of Medicine, Department of Surgery & Cancer

Clinical SL in Medical Oncology (Gynaecological Oncology)
 
 
 
//

Contact

 

j.krell

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lythgoe:2021:10.1016/j.annonc.2021.08.1189,
author = {Lythgoe, M and Cleary, S and Kalofonou, F and Grunewald, T and Miller, R and Cartwright, D and Glasspool, RM and Jones, R and Rossides, S and Ratnakumaran, R and Michael, A and McNeish, I and Tookman, L and Krell, J},
doi = {10.1016/j.annonc.2021.08.1189},
journal = {Annals of Oncology},
pages = {S742--S742},
title = {747P Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study},
url = {http://dx.doi.org/10.1016/j.annonc.2021.08.1189},
volume = {32},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundEpithelial Ovarian Cancer (EOC) is the 5th leading cause of female cancer deaths. Despite high responses to first-line therapy, 5-year survival remains poor at 29%. Rucaparib is a small molecule PARP inhibitor (PARPi) approved as monotherapy for maintenance treatment of recurrent EOC with prior complete/partial response to platinum-based chemotherapy, on the basis of the ARIEL3 trial. Despite the validity of clinical trial evidence, applicability to routine practice is limited and real-world evidence (RWE) is mandated.MethodsWe performed a multi-center retrospective study of patients with advanced EOC receiving rucaparib in the UK from June 2018, via an early access program.Results119 patients were included, with a median age of 66 years (range 26-89). Median ECOG at commencement was 1 (0-3). 91% (n=108) had high grade serous carcinoma and 24% (n=29) germline/somatic BRCA1/2mutation (BRCAm). Prior to rucaparib, patients had a median of 3 therapies (range 1-9) with 8% (n=10) receiving an alternate PARPi. Overall progression free survival (PFS) was 7.5 months (1.1-37.4), with a higher PFS of 9.1 months (1.1-35.5) in BRCAm patients. This is lower than observed in ARIEL3. However, if similar inclusion/exclusion criteria are applied to our RWE population, findings are analogous, with PFS of 10.2 and 16.6 months in the overall and BRCAm groups respectively. Treatment-related toxicity (any grade) was reported in 88% (n=105) of patients, most prevalent being nausea, fatigue, anaemia and other blood dyscrasias. 26% (n=32) of patients experienced a CTCAE grade 3/4 toxicity and 58% (n=69) required dose interruption/reduction. 13% (n=16) of patients discontinued therapy due to a treatment related adverse effect: most frequently fatigue, nausea or thrombocytopenia. No haematological malignancies were observed.ConclusionsOverall we found a lower incidence of any grade and grade 3/4 toxicity, and furthermore equivalent discontinuation rates to ARIEL3. A lower overall PFS
AU  - Lythgoe,M
AU  - Cleary,S
AU  - Kalofonou,F
AU  - Grunewald,T
AU  - Miller,R
AU  - Cartwright,D
AU  - Glasspool,RM
AU  - Jones,R
AU  - Rossides,S
AU  - Ratnakumaran,R
AU  - Michael,A
AU  - McNeish,I
AU  - Tookman,L
AU  - Krell,J
DO  - 10.1016/j.annonc.2021.08.1189
EP  - 742
PY  - 2021///
SN  - 0923-7534
SP  - 742
TI  - 747P Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
T2  - Annals of Oncology
UR  - http://dx.doi.org/10.1016/j.annonc.2021.08.1189
UR  - https://www.sciencedirect.com/science/article/pii/S0923753421034189?via%3Dihub
UR  - http://hdl.handle.net/10044/1/91878
VL  - 32
ER  -
Download